ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1357

Leptin-adjustment of the Multi-biomarker Disease Activity (MBDA) Score Reduces the Influence of Adiposity

Joshua Baker1, Jeffrey Curtis 2, David Chernoff 3 and Michael George 4, 1University of Pennsylvania, Philadelphia, PA, 2University of Alabama at Birmingham, Birmingham, AL, 3Myriad Genetics, Inc, Salt Lake City, UT, 4University of Pennsylvania, Philadelphia

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Biomarkers, Disease Activity, rheumatoid arthritis (RA) and obesity

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: RA – Diagnosis, Manifestations, & Outcomes Poster II: Treatments, Outcomes, & Measures

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Obesity and excess adiposity influence inflammatory markers and bias assessments of disease activity, most notably among women. A leptin-adjusted multi-biomarker disease activity (MBDA-LA) score has been developed to account for the effects of age, sex and adiposity and improves prediction of radiographic damage progression. We aimed 1) to determine if the adjusted measure demonstrates a reduced association with adiposity, 2) to assess the impact of the leptin-adjustment on the score over the range of adiposity, and 3) to assess relationships between MBDA scores and clinical disease activity.

Methods: Patients with RA, ages 18-75 years, were recruited from clinical practices and completed whole-body DXA to quantify fat mass indices (FMI, kg/m2). Age-, sex-, and race-specific Z-Scores were calculated based on the distributions in a healthy reference population. Clinical disease activity was assessed with the CDAI and swollen joint count. van der Heijde-Sharpe (vdHS) scores were determined at baseline by a trained radiologist. MBDA assays were performed on stored serum samples. Descriptive statistics described relationships between the FMI Z-Score and the MBDA and the MBDA-LA. Clinical disease activity, swollen joint count (SJC), and radiographic damage were also compared across categories of MBDA scores.

Results: There were 104 participants (50% female) with mean (SD) age of 56.1 (12.5) and mean BMI of 28.8 (6.9) (Table 1). The unadjusted MBDA score was strongly associated with BMI among women (Women: Rho=0.46 [p< 0.001]; Men: Rho=-0.12), while the MBDA-LA was not associated with BMI in women, and was inversely correlated in men (Women: Rho=0.17; Men: Rho=-0.32 [p=0.02]). The unadjusted MBDA score was also strongly associated with FMI Z-Score among women (Figure) (Women: Rho=0.42 [p=0.002]; Men: Rho=-0.10; p for interaction=0.01). The MBDA-LA was not significantly associated with FMI Z-Score in women or men (Female: Rho= 0.17; Male: Rho=-0.26). Leptin-adjustment reduced the MBDA score in the highest quartile of FMI in women but not men, and increased the MBDA score in the lowest FMI quartiles in both women and men (Figure); these patients in the lowest FMI quartile had the highest median swollen joint counts (p=0.05 for men, p=0.78 for women) (Figure). The MBDA-LA reclassified 4 women (8%) and 9 men (17%) into higher disease activity categories, and reclassified 2 women (4%)  and 2 men (4%) into lower categories. CDAI, SJC, and radiographic scores were similar across activity categories for the unadjusted MBDA score and MBDA-LA (Table 2).

Conclusion: Leptin-adjustment of the MBDA score reduces bias related to excess adiposity in women with RA. The adjustment results in lower MBDA scores in women with greater adiposity, and higher MBDA scores in women and men with lesser adiposity. The use of the MBDA-LA may reduce misclassification due to excess adiposity and improve identification of active disease among patients with lower adiposity. High MBDA-LA scores among men with low adiposity may reflect severe disease or excess comorbidity in this group.


MBDA_abstract_Table 1

Table 1: Baseline patient characteristics.


MBDA abstract_Table 2

Table 2: Clinical assessments across categories of the unadjusted and leptin-adjusted MBDA Scores.


abstract_figure

Figure: Associations between FMI Z-Score and unadjusted and leptin-adjusted MBDA Scores in Women and Men with RA


Disclosure: J. Baker, Bristol-Myers Squib, 5, Burns-White LLC, 5, Myriad RBM, 2; J. Curtis, AbbVie, 2, 5, Abbvie, 2, 5, AbbVie, Amgen, Bristol-Myers Squibb, Corrona, Lilly, Janssen, Myriad, Pfizer, Regeneron, Roche, and UCB, 2, 5, Amgen, 2, 5, Amgen Inc., 2, 5, BMS, 2, 5, Bristol-Myers Squibb, 2, 5, Corrona, 2, 5, Crescendo, 2, 5, Eli Lilly, 2, 5, Eli Lilly and Company, 2, 5, Genentech, 2, 5, Janseen, 5, Janssen, 2, 5, Janssen Research & Development, LLC, 2, Lilly, 2, 5, Myriad, 2, 5, Patient Centered Outcomes Research Insitute (PCORI), 2, Pfizer, 2, 5, Radius Health, Inc., 9, Regeneron, 2, 5, Roche, 2, 3, 5, Roche/Genentech, 5, UCB, 2, 5; D. Chernoff, Myriad RBM, 3; M. George, AbbVie, 5, Bristol Myers Squibb, 2, Bristol-Myers Squibb, 2.

To cite this abstract in AMA style:

Baker J, Curtis J, Chernoff D, George M. Leptin-adjustment of the Multi-biomarker Disease Activity (MBDA) Score Reduces the Influence of Adiposity [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/leptin-adjustment-of-the-multi-biomarker-disease-activity-mbda-score-reduces-the-influence-of-adiposity/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/leptin-adjustment-of-the-multi-biomarker-disease-activity-mbda-score-reduces-the-influence-of-adiposity/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology